Interestingly, immunohistochemical analysis using the hematopoietic progenitor cell marker CD31 showed that tumors from animals co-treated with kallistatin and the anti-nucleolin antibody exhibited a significantly higher blood vessel density than tumor samples from mice treated with kallistatin and nonimmune IgG. Here, NUCLEOLIN is linked to neoplasm.